Nti-Addae, Kwame W.,Waldo, Michael,O'Neil, Simon Adam,Van Alsten, John Gregg,Macikenas, Dainius,Mudunuri, Praveen,Shi, Yi,Ledeboer, Mark Willem,Jurkauskas, Valdas,Medek, Ales,Jones, Steven,Byrn, Randa
申请号：
HRP20191525
公开号：
HRP20191525T1
申请日:
2019.08.26
申请国别(地区):
HR
年份:
2019
代理人:
摘要：
Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula:are Form A of HCl salt of Compound(1)·1/2H<；sub>；2<；/sub>；O, Form F of HCl salt of Compound(1)·3H<；sub>；2<；/sub>；O, Form D of HCl salt of Compound(1),Form A of Compound(1),and Form A of tosylate salt of Compound(1).Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
